AA
ACXP icon

ACT Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

ACT Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,298
Closed -$23.5K – 74
2025
Q2 		$23.5K Buy
+2,298
New +$18.5K 0.01% 58
2025
Q1 		– Sell
-1,064
Closed -$17.3K – 58
2024
Q4 		$17.3K Buy
+1,064
New +$32K 0.01% 51

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

ACT Advisors's ACXP Position: Q3 2025 in Review

ACT Advisors sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 2,298 shares — an estimated $23.5K sold.

ACT Advisors first reported a position in ACXP in Q4 2024 and held it in 2 quarters. The position peaked at $23.5K in Q2 2025. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • ACT Advisors reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • ACT Advisors sold 2,298 Acurx Pharmaceuticals shares in Q3 2025, an estimated $23.5K.
  • ACT Advisors first reported a position in Acurx Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • ACT Advisors's Acurx Pharmaceuticals position peaked at $23.5K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on ACT Advisors's 13F filing for Q3 2025, filed 9 Oct 2025.